BRPI1012770A2 - derivados de tiofeno - Google Patents

derivados de tiofeno

Info

Publication number: BRPI1012770A2
Authority: BR; Brazil
Prior art keywords: thiophene derivatives; thiophene; derivatives
Prior art date: 2009-05-14

Application number

BRPI1012770A

Other languages

English (en)

Inventor

Guanghuai Zeng

Hesheng Zhang

Yifei Gao

Original Assignee

Tianjin Hemay Bio Tech Co Ltd

Tianjin Michele Sci Tech Dev Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-14

Filing date

2010-05-14

Publication date

2016-11-08

2010-05-14 Application filed by Tianjin Hemay Bio Tech Co Ltd, Tianjin Michele Sci Tech Dev Co Ltd filed Critical Tianjin Hemay Bio Tech Co Ltd

2016-11-08 Publication of BRPI1012770A2 publication Critical patent/BRPI1012770A2/pt

2020-10-20 Publication of BRPI1012770B1 publication Critical patent/BRPI1012770B1/pt

2021-05-25 Publication of BRPI1012770B8 publication Critical patent/BRPI1012770B8/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Virology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Hematology (AREA)
Neurology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Toxicology (AREA)
AIDS & HIV (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Transplantation (AREA)

BRPI1012770A 2009-05-14 2010-05-14 derivados de tiofeno BRPI1012770B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CN200910068831		2009-05-14
CN200910068831.1		2009-05-14
PCT/CN2010/072767 WO2010130224A1 (zh)	2009-05-14	2010-05-14	噻吩衍生物

Publications (3)

Publication Number	Publication Date
BRPI1012770A2 true BRPI1012770A2 (pt)	2016-11-08
BRPI1012770B1 BRPI1012770B1 (pt)	2020-10-20
BRPI1012770B8 BRPI1012770B8 (pt)	2021-05-25

Family

ID=43071846

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1012770A BRPI1012770B8 (pt)	2009-05-14	2010-05-14	derivados de tiofeno

Country Status (13)

Country	Link
US (4)	US8952178B2 (pt)
EP (1)	EP2431371B1 (pt)
JP (1)	JP5752114B2 (pt)
KR (1)	KR101514866B1 (pt)
CN (5)	CN107722036B (pt)
AU (1)	AU2010246749B8 (pt)
BR (1)	BRPI1012770B8 (pt)
CA (1)	CA2761845C (pt)
ES (1)	ES2441740T3 (pt)
MX (1)	MX2011012122A (pt)
RU (1)	RU2536865C2 (pt)
WO (1)	WO2010130224A1 (pt)
ZA (1)	ZA201108349B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2536865C2 (ru)	2009-05-14	2014-12-27	Тяньцзинь Химэй Байо-Тек Ко., Лтд.	Производные тиофена
US9126906B2 (en) *	2012-02-21	2015-09-08	Celgene Corporation	Asymmetric synthetic processes for the preparation of aminosulfone compounds
CN104447443B (zh) *	2014-12-05	2016-07-27	新发药业有限公司	一种阿普斯特及其中间体的制备方法
EP3280701B1 (en)	2015-04-09	2019-10-16	Zentiva K.S.	A method of chiral resolution of the key intermediate of the synthesis of apremilast and its use for the preparation of pure apremilast
CZ2015383A3 (cs)	2015-06-05	2016-12-14	Zentiva, K.S.	Způsob přípravy klíčového intermediátu apremilastu, využívající enzymatické štěpení racemických aminů
US9765026B2 (en) *	2015-08-28	2017-09-19	Scinopharm Taiwan, Ltd.	Forms of apremilast and the process of making the same
WO2017089347A1 (en)	2015-11-25	2017-06-01	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
TWI623316B (zh) *	2015-12-22	2018-05-11	Taiho Pharmaceutical Co Ltd	Antitumor effect enhancer derived from pyrrolopyrimidine compound
US10774041B2 (en)	2016-04-15	2020-09-15	Davuluri Ramamohan Rao	Process for the preparation of apremilast
CN106543050B (zh) *	2016-09-28	2018-04-10	中南大学湘雅医院	一种阿普斯特中间体的合成工艺
CN109730996B (zh) *	2017-03-01	2021-08-24	浙江大学	喹啉结构类型雄激素受体拮抗剂及其应用
US11149003B2 (en)	2017-04-04	2021-10-19	Quimica Sintetica, S.A.	Resolution of racemic beta-aminosulfone compounds
CN107011209A (zh) *	2017-05-11	2017-08-04	蚌埠中实化学技术有限公司	一种3‑甲氧基‑4‑乙氧基苯腈的合成新工艺
US10570147B2 (en)	2017-06-13	2020-02-25	Biotheryx, Inc.	Bicyclic compounds and methods of use
CN108008035B (zh) *	2017-11-23	2020-07-07	中山奕安泰医药科技有限公司	3-乙氧基-4-甲氧基苯甲醛纯度的检测方法
CN107966509B (zh) *	2017-11-23	2020-06-23	中山奕安泰医药科技有限公司	一种(s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法
CN107941945B (zh) *	2017-11-23	2020-12-22	中山奕安泰医药科技有限公司	一种3-乙氧基-4-甲氧基苯甲腈的检测方法
CN107827722B (zh) *	2017-11-23	2021-02-19	中山奕安泰医药科技有限公司	一种3-乙氧基-4-甲氧基苯甲醛的合成方法
CN107976501B (zh) *	2017-11-23	2020-08-25	中山奕安泰医药科技有限公司	一种1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法
AU2019254962C1 (en)	2018-04-17	2023-04-27	Tianjin Hemay Pharmaceutical Sci-Tech Co., Ltd	Isoindole derivatives
AU2019262284A1 (en) *	2018-05-02	2020-12-24	Tianjin Hemay Pharmaceutical Co., Ltd.	Solid form of thiophene derivative
CN109776526A (zh) *	2019-01-23	2019-05-21	西南医科大学	稠环三唑-(磺酰基)三氮烯类衍生物及其合成方法和用途
CN111821299A (zh) *	2019-04-16	2020-10-27	天津合美医药科技有限公司	噻吩衍生物用于治疗免疫球蛋白E（IgE）介导的疾病的应用
US20230141101A1 (en) *	2020-02-24	2023-05-11	Suzhou Longbotai Pharmaceuticals Co., Ltd.	Pde4 inhibitor compound and medical use thereof
JP2024545712A (ja) *	2021-12-21	2024-12-10	ガンチョウヘメイファーマシューティカルカンパニーリミテッド	チオフェン誘導体の調製
GB202306663D0 (en)	2023-05-05	2023-06-21	Union Therapeutics As	Combination therapy
CN120000644A (zh) *	2023-11-14	2025-05-16	赣州和美药业股份有限公司	中重度斑块型银屑病的治疗
CN120000646A (zh) *	2023-11-14	2025-05-16	天津合美医药科技有限公司	干燥综合征的预防或治疗

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4023048A1 (de) *	1990-07-20	1992-01-23	Basf Ag	Dicarbonsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
US6020358A (en) *	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels
AU2006200033B8 (en)	1998-10-30	2008-09-11	Celgene Corporation	Substituted phenethylsulfones and methods of reducing TNF-alpha levels
US6667316B1 (en) *	1999-11-12	2003-12-23	Celgene Corporation	Pharmaceutically active isoindoline derivatives
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en)	2002-03-20	2007-04-24	Celgene Corporation	Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
AU2003222034A1 (en)	2002-03-20	2003-10-08	Celgene Corporation	(-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en)	2002-03-20	2007-10-02	Celgene Corporation	Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7776907B2 (en)	2002-10-31	2010-08-17	Celgene Corporation	Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
NZ551669A (en)	2004-05-31	2010-07-30	Almirall Lab	Combinations comprising antimuscarinic agents and PDE4 inhibitors
BRPI0519030A2 (pt)	2004-12-13	2008-12-23	Celgene Corp	mÉtodos de tratamento, prevenÇço, ou controle de inflamaÇço das vias aÉreas e de uma doenÇa ou distérbio das vias aÉreas ou pulmonar, e, composiÇço farmacÊutica
CN100383139C (zh) *	2005-04-07	2008-04-23	天津和美生物技术有限公司	可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
GB0511066D0 (en)	2005-05-31	2005-07-06	Novartis Ag	Organic compounds
CN1939922B (zh) *	2005-09-27	2010-10-13	天津和美生物技术有限公司	可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物
WO2007042035A2 (en)	2005-10-07	2007-04-19	Aditech Pharma Ab	Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
US20070155791A1 (en)	2005-12-29	2007-07-05	Zeldis Jerome B	Methods for treating cutaneous lupus using aminoisoindoline compounds
US8007790B2 (en)	2006-04-03	2011-08-30	Stowers Institute For Medical Research	Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
WO2007139150A1 (ja)	2006-05-30	2007-12-06	The University Of Tokushima	ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤
CN101186612B (zh) *	2006-11-15	2012-10-03	天津和美生物技术有限公司	可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
ES2306595B1 (es)	2007-02-09	2009-09-11	Laboratorios Almirall S.A.	Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
WO2009002746A1 (en)	2007-06-22	2008-12-31	Decode Genetics Ehf.	Dosing schedules of leukotriene synthesis inhibitors for human therapy
EA201000219A1 (ru)	2007-07-17	2010-12-30	Комбинейторкс, Инкорпорейтед	Способ и композиция для лечения в-клеточных пролиферативных нарушений
WO2009011897A1 (en)	2007-07-17	2009-01-22	Combinatorx, Incorporated	Combinations for the treatment of b-cell proliferative disorders
WO2009013286A1 (en)	2007-07-24	2009-01-29	Novartis Ag	Organic compounds
KR20100132045A (ko)	2008-03-27	2010-12-16	셀진 코포레이션	(+)-2-[1-(3-에톡시-4-메톡시페닐)-2-메틸설포닐에틸]-4-아세틸아미노이소인돌린-1,3-디온을 포함하는 고체 형태, 이의 조성물, 및 이의 용도
WO2009151569A2 (en)	2008-06-09	2009-12-17	Combinatorx, Incorporated	Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
RU2536865C2 (ru) *	2009-05-14	2014-12-27	Тяньцзинь Химэй Байо-Тек Ко., Лтд.	Производные тиофена

2010
- 2010-05-14 RU RU2011150786/04A patent/RU2536865C2/ru active
- 2010-05-14 AU AU2010246749A patent/AU2010246749B8/en active Active
- 2010-05-14 CN CN201711006515.2A patent/CN107722036B/zh active Active
- 2010-05-14 JP JP2012510105A patent/JP5752114B2/ja active Active
- 2010-05-14 MX MX2011012122A patent/MX2011012122A/es active IP Right Grant
- 2010-05-14 CN CN2010101804238A patent/CN101885731A/zh active Pending
- 2010-05-14 EP EP10774565.5A patent/EP2431371B1/en active Active
- 2010-05-14 CN CN201711381227.5A patent/CN107964016B/zh active Active
- 2010-05-14 ES ES10774565.5T patent/ES2441740T3/es active Active
- 2010-05-14 WO PCT/CN2010/072767 patent/WO2010130224A1/zh not_active Ceased
- 2010-05-14 CA CA2761845A patent/CA2761845C/en active Active
- 2010-05-14 CN CN201710815560.6A patent/CN107501290A/zh active Pending
- 2010-05-14 US US13/320,533 patent/US8952178B2/en active Active
- 2010-05-14 CN CN201810075755.6A patent/CN108059635B/zh active Active
- 2010-05-14 BR BRPI1012770A patent/BRPI1012770B8/pt active IP Right Grant
- 2010-05-14 KR KR1020117028599A patent/KR101514866B1/ko active Active
2011
- 2011-11-14 ZA ZA2011/08349A patent/ZA201108349B/en unknown
2014
- 2014-05-19 US US14/281,289 patent/US9630975B2/en active Active
2017
- 2017-03-24 US US15/468,990 patent/US10385062B2/en active Active
2019
- 2019-07-02 US US16/460,710 patent/US10611775B2/en active Active

Also Published As

Publication number	Publication date
BRPI1012770B8 (pt)	2021-05-25
US9630975B2 (en)	2017-04-25
KR20120028893A (ko)	2012-03-23
CN107964016A (zh)	2018-04-27
RU2536865C2 (ru)	2014-12-27
CN107501290A (zh)	2017-12-22
CN107722036A (zh)	2018-02-23
EP2431371A1 (en)	2012-03-21
AU2010246749B8 (en)	2014-03-20
JP2012526731A (ja)	2012-11-01
US20190322684A1 (en)	2019-10-24
AU2010246749A8 (en)	2014-03-20
CN107964016B (zh)	2021-10-01
US10611775B2 (en)	2020-04-07
JP5752114B2 (ja)	2015-07-22
CN108059635B (zh)	2021-10-01
RU2011150786A (ru)	2013-06-20
CN101885731A (zh)	2010-11-17
US8952178B2 (en)	2015-02-10
EP2431371B1 (en)	2013-10-09
US20120107269A1 (en)	2012-05-03
MX2011012122A (es)	2012-02-28
EP2431371A4 (en)	2012-09-26
BRPI1012770B1 (pt)	2020-10-20
ES2441740T3 (es)	2014-02-06
AU2010246749B2 (en)	2013-09-05
KR101514866B1 (ko)	2015-04-24
US20140255342A1 (en)	2014-09-11
CA2761845A1 (en)	2010-11-18
CA2761845C (en)	2015-01-20
CN108059635A (zh)	2018-05-22
AU2010246749A1 (en)	2011-12-15
CN107722036B (zh)	2020-09-04
ZA201108349B (en)	2013-01-30
US20170197982A1 (en)	2017-07-13
WO2010130224A1 (zh)	2010-11-18
US10385062B2 (en)	2019-08-20

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-10	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-04-24	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-05-14	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-10-01	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-04-07	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-07-07	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-10-20	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/05/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2022-05-24	B25A	Requested transfer of rights approved	Owner name: GANZHOU HEMAY PHARMACEUTICAL CO., LTD (CN)

Publication	Publication Date	Title
BRPI1013246A2 (pt)	2016-04-05	derivados de benzofuralina
BR112012002828A2 (pt)	2015-10-13	derivados de 5-fluorpirimidinona
EP2431371A4 (en)	2012-09-26	thiophene
ECSP12011999A (es)	2012-07-31	Derivados benzamida sustituidos
BRPI1013844A2 (pt)	2016-04-12	derivados de piridina-isoxazol
BR112012015868A2 (pt)	2017-06-20	derivados de imidazolidinadiona
EP2433940A4 (en)	2012-10-10	SPIROIMIDAZOLONDERIVAT
BRPI1008749A2 (pt)	2015-08-25	Derivados de benzodiazepina
BR112012002662A2 (pt)	2016-03-22	derivados de bis-benzimidazol
BR112012004969A2 (pt)	2019-09-24	derivados de bis-benzimidazol
BRPI1006128A2 (pt)	2016-11-01	derivados de sulfonamida
DK2397480T3 (da)	2013-09-02	Diazepindionderivat
EP2462134A4 (en)	2012-12-19	N1-sulfonyl-5-FLUORPYRIMIDINON DERIVATIVES
BRPI1008774A2 (pt)	2016-03-08	espiroamida substituída
BRPI1011468A2 (pt)	2016-03-22	derivados condensados de pirrolipiridino
BRPI0915064A2 (pt)	2015-10-27	derivados de qunoxalinadiona
BRPI0913832A2 (pt)	2015-10-20	derivados de pirrolopiridinilpirimidin-2-ilamina
BR112012008108A2 (pt)	2015-09-22	derivados de xantina substituídos
BRPI1014454A2 (pt)	2016-04-05	derivados de isoxazol-pirazol
BR112012002810A2 (pt)	2015-09-15	derivados de n1-acil-5-fluoropirimidinona
DK2387580T3 (da)	2014-10-13	Deoxyactagardinderivater
BR112012016923A2 (pt)	2015-09-01	Derivados de pirazol
BRPI1007884A2 (pt)	2016-09-06	derivados de actagardina
BRPI0913234A2 (pt)	2016-01-19	derivados de tiazolilpiperidina
BRPI0922652A2 (pt)	2015-08-11	Derivados de quinazolinamida